We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
+19.02%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$2.7B
AUM Growth
-$133M
(-4.7%)
Cap. Flow
-$358M
Cap. Flow
% of AUM
-13.27%
Top 10 Holdings %
Top 10 Hldgs %
54.24%
Holding
107
New
20
Increased
12
Reduced
35
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$157M |
| 2 |
OMDA
Omada Health Inc
OMDA
|
+$42M |
| 3 |
Roivant Sciences
ROIV
|
+$36.1M |
| 4 |
CAI
Caris Life Sciences
CAI
|
+$29.6M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$17.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$104M |
| 2 |
FOLD
Amicus Therapeutics
FOLD
|
+$90.7M |
| 3 |
SLNO
Soleno Therapeutics
SLNO
|
+$80.5M |
| 4 |
VRNA
Verona Pharma
VRNA
|
+$78.2M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$42.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
CALL
Capricor Therapeutics
CAPR
$1.13B
| $993K | 0.04% |
+100,000
| New | +$1.06M |
|
77
Forte Biosciences
FBRX
$1B
| $882K | 0.03% |
+68,192
| New | +$587K |
|
78
Avalo Therapeutics
AVTX
$1.02B
| $697K | 0.03% |
139,667
-380,333
| -73% | -$1.78M |
|
79
Biodesix
BDSX
$209M
| $613K | 0.02% |
108,694
| – | – |
|
80
Lexeo Therapeutics
LXEO
$368M
| $562K | 0.02% |
139,835
| – | – |
|
81
Apyx Medical
APYX
$180M
| $338K | 0.01% |
150,000
| – | – |
|
82
KALA BIO
KALA
$14.4M
| $263K | 0.01% |
1,105
-4,447
| -80% | -$868K |
|
83
Ensysce Biosciences
ENSC
$4.35M
| $193K | 0.01% |
86,666
| – | – |
|
84
Revolution Medicines Inc Warrant
RVMDW
$102M
| $65.7K | ﹤0.01% |
250,000
| – | – |
|
85
Surrozen Inc Warrant
SRZNW
| $3.02K | ﹤0.01% |
166,666
| – | – |
|
86
Acrivon Therapeutics
ACRV
$74.9M
| – | – |
-5,360,858
| Closed | -$10.9M |
|
87
Adaptive Biotechnologies
ADPT
$3.67B
| – | – |
-930,972
| Closed | -$6.92M |
|
|
APLT
88
DELISTED
Applied Therapeutics
APLT
| – | – |
-860,000
| Closed | -$420K |
|
89
argenx
ARGX
$53.8B
| – | – |
-59,510
| Closed | -$35.2M |
|
90
Cullinan Oncology
CGEM
$1.09B
| – | – |
-80,100
| Closed | -$606K |
|
|
CRGX
91
DELISTED
CARGO Therapeutics
CRGX
| – | – |
-2,431,085
| Closed | -$9.89M |
|
92
Delcath Systems
DCTH
$442M
| – | – |
-462,422
| Closed | -$5.89M |
|
93
DexCom
DXCM
$29.6B
| – | – |
-178,000
| Closed | -$12.2M |
|
94
CALL
Edgewise Therapeutics
EWTX
$4.28B
| – | – |
-500,000
| Closed | -$11M |
|
95
EyePoint Inc
EYPT
$1.12B
| – | – |
-1,537,274
| Closed | -$8.33M |
|
|
96
Iovance Biotherapeutics
IOVA
$2.23B
| – | – |
-12,711,788
| Closed | -$42.3M |
|
97
Disc Medicine
IRON
$2.91B
| – | – |
-150,000
| Closed | -$7.45M |
|
98
Madrigal Pharmaceuticals
MDGL
$12.8B
| – | – |
-46,500
| Closed | -$15.4M |
|
|
MREO
99
Mereo BioPharma
MREO
$49.5M
| – | – |
-876,961
| Closed | -$1.97M |
|
|
NBTX
100
Nanobiotix
NBTX
$1.92B
| – | – |
-105,053
| Closed | -$376K |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q2 2025 Portfolio in Review
As of Q2 2025, Perceptive Advisors held 107 positions worth $2.7B, down 4.7% from $2.83B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Perceptive Advisors withdrew a net $358M in Q2 2025, closing 22 positions and reducing 35 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $104M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.
Against the trend, Perceptive Advisors opened a new position in Ascendis Pharma A/S worth $166M.
- Perceptive Advisors's largest Q2 2025 buy was Ascendis Pharma A/S: 963,886 shares worth $166M.
- Perceptive Advisors added most to Neurocrine Biosciences in Q2 2025, an estimated $17.8M increase.
- Perceptive Advisors's biggest Q2 2025 reduction was Amicus Therapeutics, cutting an estimated $90.7M.
- Perceptive Advisors fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $104M.
- Perceptive Advisors's ten largest holdings make up 54% of its $2.7B portfolio in Q2 2025.
- Perceptive Advisors opened 20 new positions and closed 22 in Q2 2025.
- Perceptive Advisors's portfolio value fell 4.7% quarter-over-quarter to $2.7B.
Based on Perceptive Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.